- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1.5MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 1.3MB)
Atezolizumab – July 2022
Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL, Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq®
Last updated
28 October 2022